Evidence map›Paper›PMID 38316703›Full record

Observational studyJapanese journal of ophthalmology2024

Intraocular pressure changes during intravitreal aflibercept injection based on treat-and-extend regimen in Japanese patients with neovascular age-related macular degeneration and glaucoma.

Junichiro Honjo, Ryo Mukai, Kanako Itagaki, Keiichiro Tanaka, Koki Norikawa, Yutaka Kato, Akihito Kasai, Yukinori Sugano, Tetsuju Sekiryu

Abstract readObservational Study
PubMed Publisher
In one paragraph

Observational study in Japanese journal of ophthalmology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.5field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Junichiro HonjoDepartment of Ophthalmology, Fukushima Medical University, 1-Hikarigaoka, Fukushima, Fukushima, 960-1295, Japan.
Ryo MukaiDepartment of Ophthalmology, Fukushima Medical University, 1-Hikarigaoka, Fukushima, Fukushima, 960-1295, Japan.
Kanako ItagakiDepartment of Ophthalmology, Fukushima Medical University, 1-Hikarigaoka, Fukushima, Fukushima, 960-1295, Japan.
Keiichiro TanakaDepartment of Ophthalmology, Fukushima Medical University, 1-Hikarigaoka, Fukushima, Fukushima, 960-1295, Japan.
Koki NorikawaDepartment of Ophthalmology, Fukushima Medical University, 1-Hikarigaoka, Fukushima, Fukushima, 960-1295, Japan.
Yutaka KatoDepartment of Ophthalmology, Fukushima Medical University, 1-Hikarigaoka, Fukushima, Fukushima, 960-1295, Japan.
Akihito KasaiDepartment of Ophthalmology, Fukushima Medical University, 1-Hikarigaoka, Fukushima, Fukushima, 960-1295, Japan.
Yukinori SuganoDepartment of Ophthalmology, Fukushima Medical University, 1-Hikarigaoka, Fukushima, Fukushima, 960-1295, Japan.
Tetsuju SekiryuDepartment of Ophthalmology, Fukushima Medical University, 1-Hikarigaoka, Fukushima, Fukushima, 960-1295, Japan. sekiryu@fmu.ac.jp.
Fukushima Medical University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTo assess the changes in intraocular pressure (IOP) after intravitreal aflibercept injections in Japanese patients with neovascular age-related macular degeneration (nAMD) complicated by glaucoma. STUDY

designRetrospective observational study.

methodsWe retrospectively reviewed 27 eyes of 25 Japanese patients diagnosed with nAMD complicated by glaucoma. The patients were treated with 2 mg/0.05 ml of aflibercept and followed for 52 weeks according to a treat-and-extend (TAE) regimen after 3 consecutive monthly injections. The IOP of each eye was measured at each visit using non-contact tonometry. IOP changes as well as additional glaucoma treatments during 52 weeks were recorded.

resultsThe mean of aflibercept injections was 8.3 ± 1.9. The mean IOP at baseline was 14.0 ± 3.1 mmHg, and the mean IOP after aflibercept therapy was 13.0 ± 2.4 mmHg at the final visit (P = 0.0463). No patients received additional glaucoma treatment of eye drops or surgery.

conclusionOur results suggest that intravitreal aflibercept injections may be beneficial for patients with nAMD complicated by glaucoma.

Indexed as

GlaucomaMacular DegenerationAngiogenesis InhibitorsHumansIntraocular PressureIntravitreal InjectionsJapanReceptors, Vascular Endothelial Growth FactorRecombinant Fusion ProteinsRetrospective StudiesafliberceptAngiogenesis InhibitorsReceptors, Vascular Endothelial Growth FactorRecombinant Fusion ProteinsAfliberceptAnti-vascular endothelial growth factorGlaucomaIntraocular pressureNeovascular age related macular degeneration

Identifiers

PMID38316703
OpenAlexW4391573685

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.